Get the latest on the Insulin Aspart (NovoLog, Fiasp) shortage in 2026. Learn what's causing it, what it costs now, and how to find it in stock.
If you rely on Insulin Aspart to manage your diabetes, the past year has been anything but predictable. Pharmacy shelves that used to reliably stock your NovoLog or Fiasp have been hit-or-miss, and you're probably wondering: Is this still going on? And when will it end?
Here's the most current information we have, written in plain English so you can make informed decisions about your care.
Yes. As of early 2026, Insulin Aspart remains on the ASHP (American Society of Health-System Pharmacists) drug shortage list.
The shortage isn't across every form and brand equally. Here's the breakdown:
So while Insulin Aspart hasn't disappeared entirely, the most familiar forms many patients were using are gone. That's what's causing the disruption.
Several factors are at play simultaneously:
Novo Nordisk made a strategic decision to streamline its insulin offerings. They cut list prices by up to 75% on key products as of January 1, 2026, but also discontinued their unbranded biologic versions and older delivery devices. For patients, this means the cheaper generic-like options that were available in 2024-2025 have been pulled from shelves.
The FDA approved two Insulin Aspart biosimilars in 2025: Merilog (February 2025) and Kirsty (July 2025). These are great news long-term, but manufacturing and distributing new biologic products takes time. Not every pharmacy has them in stock yet.
Fiasp FlexTouch pens experienced shortages starting in April 2024, with disruptions projected into early 2026 in some regions. While Novo Nordisk has worked to restore supply, the intermittent nature of availability has been frustrating for patients.
Pricing has actually improved, even as supply has been spotty:
For more details on every way to save, read our full guide: How to save money on Insulin Aspart in 2026.
Kirsty (insulin aspart-xjhz) is a game-changer. As the first interchangeable biosimilar to NovoLog, your pharmacist can substitute it directly — no new prescription needed from your doctor. This should help ease supply pressure as it becomes more widely stocked.
Merilog (insulin aspart-szjj) by Sanofi is a biosimilar (not interchangeable), so you may need an updated prescription to use it. But it's clinically equivalent to NovoLog and adds another option to the supply chain.
Novo Nordisk's price reductions that took effect January 1, 2026, cover Fiasp and other insulin products. Combined with the $35/month Medicare cap and manufacturer savings programs, out-of-pocket costs are lower than they've been in years for many patients.
Here's your action plan:
For a step-by-step guide, see: How to find Insulin Aspart in stock near you.
The Insulin Aspart shortage in 2026 is real, but it's evolving — and mostly in a positive direction. Prices are coming down. Biosimilars are entering the market. And tools like Medfinder make it easier than ever to find what you need.
The key is to stay informed, act early, and keep your healthcare team in the loop. Don't wait until your last pen or vial to start looking — plan ahead and explore all your options.
We'll keep updating this article as the situation changes. Bookmark this page and check back for the latest.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
